Cargando…

Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A retrospective cohort study of older Medicare patients

OBJECTIVE: In vitro evidence suggests insulin glargine promotes tumors; observational human studies are conflicting. We aimed to expand understanding of this potential treatment risk. RESEARCH DESIGN AND METHODS: This retrospective cohort study of type 2 diabetic patients >68 years old used Medic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morden, Nancy E., Liu, Stephen K., Smith, Jeremy, Mackenzie, Todd A., Skinner, Jonathan, Korc, Murray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161263/ https://www.ncbi.nlm.nih.gov/pubmed/21775752 http://dx.doi.org/10.2337/dc11-0699

Ejemplares similares

Response to Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A Retrospective Cohort Study of Older Medicare Patients. Diabetes Care 2011;34:1965–1971
por: Morden, Nancy E., et al.
Publicado: (2012)

Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer: A Retrospective Cohort Study of Older Medicare Patients. Diabetes Care 2011;34:1965–1971
por: Badrick, Ellena L., et al.
Publicado: (2012)

Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study
por: Mackenzie, Todd A., et al.
Publicado: (2016)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Receipt of Medications for Chronic Disease During the First 2 Years of the COVID-19 Pandemic Among Enrollees in Fee-for-Service Medicare
por: Morden, Nancy E., et al.
Publicado: (2023)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage
por: Everhart, Alexander, et al.
Publicado: (2021)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine
por: Ioacara, Sorin, et al.
Publicado: (2015)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Commentary: Don’t Further Privatize Medicare
por: Lipschutz, David A.
Publicado: (2019)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Racial differences in low value care among older adult Medicare patients in US health systems: retrospective cohort study
por: Ganguli, Ishani, et al.
Publicado: (2023)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study
por: Arnolds, Sabine, et al.
Publicado: (2010)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
por: Bu, Shi, et al.
Publicado: (2017)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes
por: Jovanovič, Lois, et al.
Publicado: (2013)

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

Insulin Glargine Controversy: A Tribute to the Editorial Team at Diabetologia
por: Butler, Peter C.
Publicado: (2009)

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
por: Sommerfeld, Mark R., et al.
Publicado: (2010)

Insulin Glargine Safety in Pregnancy: A transplacental transfer study
por: Pollex, Erika K., et al.
Publicado: (2010)

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
por: Hilgenfeld, Rolf, et al.
Publicado: (2014)

A possible link between insulin glargine and malignancy: the facts
por: Mollentze, WF
Publicado: (2009)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
por: Thomann, Robert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1davlrf5jjtula59mvgf2p1ntt